MRSH — Marsh & McLennan Companies, Inc.

As of 2026-08-27, sentiment is balanced: Q2 2026 adjusted EPS of $2.96 beat by $0.07 and the dividend was raised 10%, but 22 of 34 analysts rate the stock Hold and the consensus target of $203.43 implies only ~7% upside from $190. Reported GAAP margins have compressed in 2026, and modest insider selling has been offset by institutional accumulation, leaving the tape in a neutral-to-cautiously-optimistic posture.

Revenue has compounded steadily: TTM revenue through 6/30/2026 was $27.95B, up about 8.3% from the prior TTM, with Q2 2026 revenue up 6.2% YoY. Profitability is a different story: Q1 2026 operating margin dropped to 23.1% from 28.4% in Q1 2025 and 29.7% in Q1 2024, while Q2 2026 operating margin was 25.7% versus 26.2% a year earlier. TTM net income declined roughly 3.6% despite revenue growth, so the trend is decelerating GAAP earnings on a still-solid top line. The Q2 adjusted-EPS beat ($2.96 vs $2.89) suggests some of the GAAP weakness reflects items management excludes, but the core margin trend is still down year-over-year rather than a one-quarter blip.

As of 2026-08-27, at $190 the stock trades at 23.1x TTM earnings and 3.24x sales, below its own 5-year averages of 25.5x and 4.03x. Forward P/E is about 18.2x on the next-FY EPS estimate of $10.45. That makes it modestly cheap versus its own history, but the discount is partly warranted by the current GAAP margin compression. On forward earnings, the valuation is fair to slightly attractive, not expensive.

The market is in show-me mode: at 18.2x forward EPS, the price is not pricing in aggressive growth or a major margin recovery. If the $10.45 consensus EPS is achievable and margins stabilize, the stock looks cheap; if margin compression continues, the forward multiple has some cushion but estimates will likely fall. Watch revisions as the key tell - rising forward EPS with a stable multiple is the bullish playbook, while declining estimates would push the stock toward the lower end of its 52-week range.

As of 2026-08-27, RSI(14) at 53.5 is neutral - neither overbought nor oversold. Price is 0.3% below the 20-day SMA, 4.5% above the 50-day SMA, and 6.9% above the 200-day SMA, so the intermediate trend is up while the short-term path is flat. With a 52-week range of $156.60-$207.83, the better entry is a pullback toward the 50-day near $182 or a breakout above $207.83, not at current parity with the 20-day.

• Treasury yield volatility and shifting rate expectations create cross-currents for financials; easing yields in late August 2026 have helped lift risk sentiment.
• The P&C insurance pricing cycle is moderating, which is a mild headwind to organic growth in Risk & Insurance Services.
• Corporate cost discipline is slowing discretionary consulting demand, pressuring Mercer and Oliver Wyman growth.
• Wage inflation and acquisition integration costs are weighing on GAAP expenses; the Thrive cost-savings program is the offset.
• Bond market volatility can affect investment income on premiums held and pension/benefit consulting demand.

• Q3 2026 earnings expected in late October 2026 - focus on organic growth, margin trajectory, and McGriff integration updates.
• McGriff acquisition ramping into results plus additional mid-market bolt-on M&A.
• Thrive cost-savings initiative delivering structural margin relief.
• Positive forward EPS estimate revisions if adjusted-EPS momentum continues.

• Continued GAAP margin compression or operating deleverage in consulting.
• Moderating P&C pricing reducing organic revenue growth.
• Balance-sheet leverage (D/E 1.47) and integration risk from McGriff and bolt-on deals.
• Higher interest costs on roughly $18.9B of long-term debt, plus recession-driven weakness in discretionary consulting and transaction activity.

MRSH is a high-quality, defensive insurance broker with durable free cash flow (~$4.8B TTM), a 2.1% dividend yield, and a reasonable forward multiple. But the current fundamental trajectory is one of decelerating GAAP margins and earnings, so I would not chase the stock here; it is more of a hold/accumulate-on-weakness than a fresh buy until margin trends stabilize or forward estimates start moving up.

I applied a 20.0x P/E multiple to the next-FY estimated EPS of $10.45, yielding $209.00. The 20x multiple is a deliberate discount to MRSH's 5-year average P/E of 25.5x to reflect current GAAP margin compression, but it is above the current 18.2x forward multiple to reflect durable FCF, the 2.1% dividend yield, low beta, and the Q2 adjusted-EPS beat.